SCHEDULE: Adage Capital Discloses 7.88% Stake in Tango Therapeutics
Beneficial Ownership Disclosure
Adage Capital Management, along with Robert Atchinson and Phillip Gross, reported a 7.88% beneficial ownership stake in Tango Therapeutics, Inc. as of December 31, 2025.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 10,607,924 shares of Tango Therapeutics, Inc. Common Stock.
- This ownership represents 7.88% of the total outstanding Common Stock of Tango Therapeutics, Inc.
- The shares are held with shared voting power and shared dispositive power among the reporting persons.
- The percentage of class is calculated based on 134,677,094 shares of Common Stock outstanding as of November 1, 2025, as reported in the Company's Form S-3 filed on November 21, 2025.
- The filing is a Schedule 13G, indicating that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive development, as it indicates significant institutional interest in Tango Therapeutics, which can often be a precursor to increased investor confidence and potential stability in the stock.
Positives
- A significant institutional investor, Adage Capital Management, holding a substantial stake (7.88%) can be viewed as a vote of confidence in Tango Therapeutics, Inc.
Future Outlook
This filing does not contain any forward-looking statements or guidance from Tango Therapeutics, Inc. or the reporting persons regarding the company's future performance or strategic direction.
Industry Context
StockSavvy.ai notes that institutional ownership disclosures like this Schedule 13G are common in the biotechnology sector, where investment firms often take significant positions in companies with promising drug pipelines. Adage Capital Management is a well-known hedge fund, and its stake in Tango Therapeutics could signal its belief in the company's long-term potential within the competitive oncology drug development landscape.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional holder may increase confidence among existing and potential shareholders, potentially influencing stock valuation.
- Company Management: Awareness of a large institutional stake may influence management's strategic decisions and communication with the investment community.
Key Dates
| Date | Description |
|---|---|
| 2025-11-01 | Date as of which 134,677,094 shares of Common Stock were outstanding, used for percentage calculation. |
| 2025-11-21 | Date of the Company's Registration Statement on Form S-3, which reported the outstanding shares. |
| 2025-12-31 | Date of event which requires the filing of this statement (reporting period end). |
| 2026-02-12 | Date the Schedule 13G was signed and filed by the Reporting Persons. |
Keywords
Tango Therapeutics, Adage Capital Management, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Schedule 13G, Biotechnology, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.